DALLAS, December 8, 2011 /PRNewswire/ --
The report "Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)" analyzes and studies the major market drivers, restraints, and opportunities in geographies such as North America, Europe, and Japan.
Browse market data tables and in-depth TOC on "Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)".
Early buyers will receive 10% customization on reports.
Chronic lymphocytic leukemia is also known as chronic lymphoid leukemia. It can be described as a slow increase in the number of white blood cells in the blood and the bone marrow. White blood cells guard the body from infections caused by bacteria. Chronic lymphocytic leukemia is divided by the type of lymphocyte involved, such as B-cell or T-cell. Chronic lymphocytic leukemia (CLL) accounts for 35% of the total leukemia.
The chronic lymphocytic leukemia therapeutics market in G8 countries was valued at $437 million in 2010 and is expected to grow at a CAGR of 13.43% from 2015 to 2020. Campath accounted for the largest share; i.e. 42.32% of the chronic lymphocytic leukemia therapeutics market [ http://www.marketsandmarkets.com/Market-Reports/chronic-lymphocytic-leukemia-therapeutics-market-519.html ] in G8 countries in 2010. However, in 2020, the market is expected to be dominated by Arzerra drug and GA101/RG7159 molecule, with sales amounting to $603 million and $994 million respectively.
According to WHO, chronic lymphocytic leukemia is expected to be more prominent in the developed world such as North America and Europe due to genetic factors. The other causes such as environmental factors and radiation exposure are also the causative of chronic lymphocytic leukemia. Global incidence of chronic lymphocytic leukemia was 94,960 in 2008 with the developing countries. Total 123,379 new cases were recorded in 2010 with 199,472 and 282,683 as the predicted new cases for 2015 and 2020.
The U.S. dominates the leukemia drug market in North America with 90.19% share; whereas Germany dominates the market of Europe with 20.49% share.
The major players in the market include F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline Pharmaceuticals Limited (U.K.), Biogen Idec (U.S.), Celgene Corporation (U.S.), Genmab A/S (Denmark), Cephalon Inc. (U.S.), Genentech Inc. (U.S.) and Genzyme Corporation (U.S.).
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical, pharmaceuticals [ http://www.marketsandmarkets.com/pharmaceutical-market-research-3.html ], semiconductor and electronics, and telecommunications and IT.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website http://www.marketsandmarkets.com.
7557 Rambler Road,
Suite 727, Dallas, TX 75231
MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com/
Copyright©2010 PR Newswire.
All rights reserved